Do analysts recommend ALVR or MBIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Mustang Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, ALVR or MBIO?

Mustang Bio is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AlloVir N/A N/A -$190.42M -$20.23 N/A Mustang Bio N/A N/A -$1.92M -$0.45 N/A

Is ALVR or MBIO more profitable?

Mustang Bio's return on equity of -34.23% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets AlloVir N/A -71.03% -61.27% Mustang Bio N/A -34.23% -17.55%

Do analysts prefer MBIO or BCDA?

BioCardia has a consensus price target of $25.00, indicating a potential upside of 2,280.95%. Given BioCardia's stronger consensus rating and higher probable upside, analysts plainly believe BioCardia is more favorable than Mustang Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mustang Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioCardia 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation and earnings, MBIO or BCDA?

BioCardia is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mustang Bio N/A N/A -$1.92M -$0.45 N/A BioCardia N/A N/A -$8.23M -$0.64 N/A

Is MBIO or BCDA more profitable?

Mustang Bio's return on equity of -34.23% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets Mustang Bio N/A -34.23% -17.55% BioCardia N/A -569.36% -183.15%

Do analysts prefer DYAI or MBIO?

Dyadic International currently has a consensus price target of $3.00, indicating a potential upside of 623.07%. Given Dyadic International's stronger consensus rating and higher possible upside, equities analysts plainly believe Dyadic International is more favorable than Mustang Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dyadic International 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Mustang Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer MBIO or GNTA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mustang Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, MBIO or GNTA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mustang Bio N/A N/A -$1.92M -$0.45 N/A Genenta Science N/A N/A -$7.39M N/A N/A

Is MBIO or GNTA more profitable?

Genenta Science's return on equity of 0.00% beat Mustang Bio's return on equity. Company Net Margins Return on Equity Return on Assets Mustang Bio N/A -34.23% -17.55% Genenta Science N/A N/A N/A

Do analysts recommend MBIO or APLT?

Applied Therapeutics has a consensus target price of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Applied Therapeutics is more favorable than Mustang Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mustang Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Applied Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is MBIO or APLT more profitable?

Mustang Bio's return on equity of -34.23% beat Applied Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Mustang Bio N/A -34.23% -17.55% Applied Therapeutics N/A -340.84% -175.00%

Mustang Bio (MBIO) Competitors

$0.51 -0.02 (-3.69%)

As of 09/23/2026 03:59 PM Eastern

Compare

MBIO vs. ALVR, BCDA, DYAI, GNTA, and APLT

Should you buy Mustang Bio stock or one of its competitors? Mustang Bio's main competitors and comparable companies include AlloVir (ALVR), BioCardia (BCDA), Dyadic International (DYAI), Genenta Science (GNTA), and Applied Therapeutics (APLT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Mustang Bio compare to AlloVir?

AlloVir (NASDAQ:ALVR) and Mustang Bio (NASDAQ:MBIO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Mustang Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

66.1% of AlloVir shares are owned by institutional investors. Comparatively, 10.0% of Mustang Bio shares are owned by institutional investors. 32.1% of AlloVir shares are owned by insiders. Comparatively, 4.0% of Mustang Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

AlloVir has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market. Comparatively, Mustang Bio has a beta of 2.05, suggesting that its share price is 105% more volatile than the broader market.

In the previous week, AlloVir's average media sentiment score of 0.00 equaled Mustang Bio'saverage media sentiment score.

Company	Overall Sentiment
AlloVir	Neutral
Mustang Bio	Neutral

Mustang Bio's return on equity of -34.23% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
Mustang Bio	N/A	-34.23%	-17.55%

Mustang Bio is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
Mustang Bio	N/A	N/A	-$1.92M	-$0.45	N/A

Summary

Mustang Bio beats AlloVir on 6 of the 9 factors compared between the two stocks.

How does Mustang Bio compare to BioCardia?

Mustang Bio (NASDAQ:MBIO) and BioCardia (NASDAQ:BCDA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

Mustang Bio's return on equity of -34.23% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mustang Bio	N/A	-34.23%	-17.55%
BioCardia	N/A	-569.36%	-183.15%

BioCardia is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mustang Bio	N/A	N/A	-$1.92M	-$0.45	N/A
BioCardia	N/A	N/A	-$8.23M	-$0.64	N/A

Mustang Bio has a beta of 2.05, suggesting that its stock price is 105% more volatile than the broader market. Comparatively, BioCardia has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market.

BioCardia has a consensus price target of $25.00, indicating a potential upside of 2,280.95%. Given BioCardia's stronger consensus rating and higher probable upside, analysts plainly believe BioCardia is more favorable than Mustang Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mustang Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

10.0% of Mustang Bio shares are held by institutional investors. Comparatively, 20.6% of BioCardia shares are held by institutional investors. 4.0% of Mustang Bio shares are held by insiders. Comparatively, 17.4% of BioCardia shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, BioCardia had 4 more articles in the media than Mustang Bio. MarketBeat recorded 4 mentions for BioCardia and 0 mentions for Mustang Bio. BioCardia's average media sentiment score of 0.75 beat Mustang Bio's score of 0.00 indicating that BioCardia is being referred to more favorably in the news media.

Company	Overall Sentiment
Mustang Bio	Neutral
BioCardia	Positive

Summary

BioCardia beats Mustang Bio on 7 of the 13 factors compared between the two stocks.

How does Mustang Bio compare to Dyadic International?

Dyadic International (NASDAQ:DYAI) and Mustang Bio (NASDAQ:MBIO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Dyadic International has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market. Comparatively, Mustang Bio has a beta of 2.05, indicating that its share price is 105% more volatile than the broader market.

In the previous week, Dyadic International's average media sentiment score of 0.00 equaled Mustang Bio'saverage media sentiment score.

Company	Overall Sentiment
Dyadic International	Neutral
Mustang Bio	Neutral

28.0% of Dyadic International shares are held by institutional investors. Comparatively, 10.0% of Mustang Bio shares are held by institutional investors. 20.9% of Dyadic International shares are held by company insiders. Comparatively, 4.0% of Mustang Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Dyadic International currently has a consensus price target of $3.00, indicating a potential upside of 623.07%. Given Dyadic International's stronger consensus rating and higher possible upside, equities analysts plainly believe Dyadic International is more favorable than Mustang Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Mustang Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Mustang Bio has a net margin of 0.00% compared to Dyadic International's net margin of -201.43%. Mustang Bio's return on equity of -34.23% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyadic International	-201.43%	-2,920.31%	-84.77%
Mustang Bio	N/A	-34.23%	-17.55%

Mustang Bio has lower revenue, but higher earnings than Dyadic International. Dyadic International is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyadic International	$3.09M	5.38	-$7.36M	-$0.23	N/A
Mustang Bio	N/A	N/A	-$1.92M	-$0.45	N/A

Summary

Dyadic International beats Mustang Bio on 7 of the 13 factors compared between the two stocks.

How does Mustang Bio compare to Genenta Science?

Mustang Bio (NASDAQ:MBIO) and Genenta Science (NASDAQ:GNTA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mustang Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Genenta Science's return on equity of 0.00% beat Mustang Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mustang Bio	N/A	-34.23%	-17.55%
Genenta Science	N/A	N/A	N/A

10.0% of Mustang Bio shares are owned by institutional investors. Comparatively, 15.1% of Genenta Science shares are owned by institutional investors. 4.0% of Mustang Bio shares are owned by insiders. Comparatively, 29.0% of Genenta Science shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Mustang Bio has a beta of 2.05, indicating that its share price is 105% more volatile than the broader market. Comparatively, Genenta Science has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mustang Bio	N/A	N/A	-$1.92M	-$0.45	N/A
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A

In the previous week, Mustang Bio's average media sentiment score of 0.00 equaled Genenta Science'saverage media sentiment score.

Company	Overall Sentiment
Mustang Bio	Neutral
Genenta Science	Neutral

Summary

Genenta Science beats Mustang Bio on 4 of the 6 factors compared between the two stocks.

How does Mustang Bio compare to Applied Therapeutics?

Mustang Bio (NASDAQ:MBIO) and Applied Therapeutics (NASDAQ:APLT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends.

Mustang Bio has a beta of 2.05, indicating that its share price is 105% more volatile than the broader market. Comparatively, Applied Therapeutics has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market.

In the previous week, Applied Therapeutics had 1 more articles in the media than Mustang Bio. MarketBeat recorded 1 mentions for Applied Therapeutics and 0 mentions for Mustang Bio. Mustang Bio's average media sentiment score of 0.00 equaled Applied Therapeutics'average media sentiment score.

Company	Overall Sentiment
Mustang Bio	Neutral
Applied Therapeutics	Neutral

Applied Therapeutics has a consensus target price of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Applied Therapeutics is more favorable than Mustang Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mustang Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

10.0% of Mustang Bio shares are held by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are held by institutional investors. 4.0% of Mustang Bio shares are held by company insiders. Comparatively, 1.6% of Applied Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Mustang Bio has higher earnings, but lower revenue than Applied Therapeutics. Mustang Bio is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mustang Bio	N/A	N/A	-$1.92M	-$0.45	N/A
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A

Mustang Bio's return on equity of -34.23% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mustang Bio	N/A	-34.23%	-17.55%
Applied Therapeutics	N/A	-340.84%	-175.00%

Summary

Applied Therapeutics beats Mustang Bio on 8 of the 12 factors compared between the two stocks.

Get Mustang Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MBIO vs. The Competition

Export

Metric	Mustang Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.02M	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-1.14	13.88	274.07	25.69
Price / Sales	N/A	1,356.95	643.13	79.17
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	0.39	15.40	10.47	6.32
Net Income	-$1.92M	-$22.82M	$3.49B	$359.73M
7 Day Performance	4.35%	-1.71%	-0.67%	0.17%
1 Month Performance	-7.24%	-6.18%	-3.17%	-3.27%
1 Year Performance	-68.43%	30.64%	15.13%	5.58%

Mustang Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MBIO Mustang Bio	0.3268 of 5 stars	$0.51 -3.7%	N/A	-67.2%	$4.02M	N/A	N/A	4	Gap Down
ALVR AlloVir	N/A	$3.25 +1.4%	N/A	-26.4%	$16.37M	N/A	N/A	110	High Trading Volume
BCDA BioCardia	3.5621 of 5 stars	$1.05 -2.8%	$25.00 +2,281.0%	-25.5%	$16.35M	$60K	N/A	21	News Coverage Gap Down
DYAI Dyadic International	2.4032 of 5 stars	$0.40 -0.2%	$3.00 +650.0%	-61.6%	$16.07M	$3.09M	N/A	5
GNTA Genenta Science	0.8907 of 5 stars	$0.70 +4.0%	N/A	-77.9%	$15.98M	N/A	N/A	9

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MBIO) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mustang Bio (MBIO) Competitors

MBIO vs. ALVR, BCDA, DYAI, GNTA, and APLT

How does Mustang Bio compare to AlloVir?

Summary

How does Mustang Bio compare to BioCardia?

Summary

How does Mustang Bio compare to Dyadic International?

Summary

How does Mustang Bio compare to Genenta Science?

Summary

How does Mustang Bio compare to Applied Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBIO vs. The Competition

Mustang Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mustang Bio (MBIO) Competitors

MBIO vs. ALVR, BCDA, DYAI, GNTA, and APLT

How does Mustang Bio compare to AlloVir?

Do analysts recommend ALVR or MBIO?

Do institutionals & insiders believe in ALVR or MBIO?

Which has more risk and volatility, ALVR or MBIO?

Does the media prefer ALVR or MBIO?

Is ALVR or MBIO more profitable?

Which has higher earnings & valuation, ALVR or MBIO?

Summary

How does Mustang Bio compare to BioCardia?

Is MBIO or BCDA more profitable?

Which has stronger valuation and earnings, MBIO or BCDA?

Which has more volatility & risk, MBIO or BCDA?

Do analysts prefer MBIO or BCDA?

Do insiders and institutionals believe in MBIO or BCDA?

Does the media favor MBIO or BCDA?

Summary

How does Mustang Bio compare to Dyadic International?

Which has more volatility and risk, DYAI or MBIO?

Does the media prefer DYAI or MBIO?

Do insiders & institutionals hold more shares of DYAI or MBIO?

Do analysts prefer DYAI or MBIO?

Is DYAI or MBIO more profitable?

Which has preferable valuation and earnings, DYAI or MBIO?

Summary

How does Mustang Bio compare to Genenta Science?

Do analysts prefer MBIO or GNTA?

Is MBIO or GNTA more profitable?

Do insiders & institutionals hold more shares of MBIO or GNTA?

Which has more volatility and risk, MBIO or GNTA?

Which has preferable valuation and earnings, MBIO or GNTA?

Does the media prefer MBIO or GNTA?

Summary

How does Mustang Bio compare to Applied Therapeutics?

Which has more risk & volatility, MBIO or APLT?

Does the media favor MBIO or APLT?

Do analysts recommend MBIO or APLT?

Do institutionals & insiders believe in MBIO or APLT?

Which has higher valuation and earnings, MBIO or APLT?

Is MBIO or APLT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBIO vs. The Competition

Mustang Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools